Nubeqa
Bayer’s Nubeqa secures NICE recommendation for hormone-relapsed prostate cancer at risk of metastasis
October 23, 2020Medical Communications, Sales and Marketing Bayer, NCIE, Nubeqa, pharma
NICE has given its recommendation to Bayer’s androgen receptor inhibitor Nubeqa (darolutamide) in combination with androgen deprivation therapy (ADT) for …
Bayer’s Nubeqa combo approved in Europe for non-metastatic castration-resistant prostate cancer
March 31, 2020Manufacturing and Production, Research and Development Bayer, Cancer, Europe, Nubeqa, prostate cancer
The European Commission has given the green light to Bayer’s non-steroidal androgen receptor inhibitor Nubeqa (darolutamide), jointly developed with Orion, …
Bayer and Orion’s Nubeqa secures FDA approval in non-metastatic castration-resistant prostate cancer
July 31, 2019Research and Development, Sales and Marketing Bayer, Cancer, Nubeqa, orion, pharma, prostate cancer
The FDA has awarded approval under its Priority Review pathway to Nubeqa (darolutamide) for the treatment of non-metastatic castration-resistant prostate …
Latest content
